A Clinical Multicenter Trial of Recombinant Human Interferon Gamma in Tuberculosis (GAM2022) Experience with the Use of Human Recombinant Interferon Gamma in TB Practice.

Infectious disorders drug targets Pub Date : 2025-01-27 DOI:10.2174/0118715265329137250102103507

Veronika E Izosimova, Natal'ja A Barmina, Marija P Zharikova, Oleg Ye Alekseyev, Oxana A Ryzhkova, Marat H Sayfulin, Natal'ja A Popova, Mihail A Andreyev, Svetlana G Gagarina, Raisa M Rysdauletova, Natal'ja G Kamaeva, Anastasiya G Samoylova, Marija I Romanova

{"title":"A Clinical Multicenter Trial of Recombinant Human Interferon Gamma in Tuberculosis (GAM2022) Experience with the Use of Human Recombinant Interferon Gamma in TB Practice.","authors":"Veronika E Izosimova, Natal'ja A Barmina, Marija P Zharikova, Oleg Ye Alekseyev, Oxana A Ryzhkova, Marat H Sayfulin, Natal'ja A Popova, Mihail A Andreyev, Svetlana G Gagarina, Raisa M Rysdauletova, Natal'ja G Kamaeva, Anastasiya G Samoylova, Marija I Romanova","doi":"10.2174/0118715265329137250102103507","DOIUrl":null,"url":null,"abstract":"Background: In this article, we present the results of a multicenter clinical trial of IFN-γ in patients with drug-susceptible and drug-resistant pulmonary Tuberculosis (TB) in routine clinical practice.Objective: This study aimed to confirm the efficacy and safety of IFN-γ administered to patients with TB.Methods: All patients were diagnosed with TB after being tested by bacterioscopic and molecular genetic methods and had no contraindications to standard chemotherapy.Results: Recombinant human IFN-γ proved high efficacy in multi-center clinical trials in routine TB practice.Conclusion: The results show that IFN-γ is efficient and safe in the treatment of pulmonary tuberculosis.","PeriodicalId":101326,"journal":{"name":"Infectious disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious disorders drug targets","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0118715265329137250102103507","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: In this article, we present the results of a multicenter clinical trial of IFN-γ in patients with drug-susceptible and drug-resistant pulmonary Tuberculosis (TB) in routine clinical practice.

Objective: This study aimed to confirm the efficacy and safety of IFN-γ administered to patients with TB.

Methods: All patients were diagnosed with TB after being tested by bacterioscopic and molecular genetic methods and had no contraindications to standard chemotherapy.

Results: Recombinant human IFN-γ proved high efficacy in multi-center clinical trials in routine TB practice.

Conclusion: The results show that IFN-γ is efficient and safe in the treatment of pulmonary tuberculosis.

查看原文